Apellis Pharmaceuticals APLS 深 滬
已收盤 10-24 16:00:00 美东时间
28.17
-0.440
-1.54%
華盛通- 最 高28.98
- 今 開28.61
- 成交量 126.56万股
- 最 低 28.05
- 昨 收 28.61
- 總市值 35.49亿
- 52周最高 35.72
- 市盈率 靜 --
- 換手率 1.00%
- 52周最低 16.10
- 委 比 77.63%
- 總股本 1.26亿
- 歷史最高 94.75
- 量 比 0.44
- 振 幅 3.25%
- 歷史最低 11.45
- 每 手 1
- 風險率 5.16%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Apellis Highlights New Phase 3 Data Showing EMPAVELI Sustains Kidney Function And Proteinuria Reduction In Rare Kidney Diseases
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) today announced new data from the open-label period of the Phase 3 VALIANT study that reinforce the robust and sustained efficacy of EMPAVELI® (pegcetacoplan), a C3
10-20 19:13
Altisource Portfolio Solutions S.A. Schedules Third Quarter 2025 Conference Call
Altisource Portfolio Solutions S.A. (NASDAQ: ASPS) will report its third quarter 2025 earnings on October 23, 2025. A press release and presentation will be available on Altisource’s website under Investor Relations. The company will host a conference call at 8:30 a.m. EDT on the same day, with a live webcast link provided on the website. Participants should register 15 minutes prior to the call. A replay will be available approximately two hours...
10-20 14:52
New One-Year Data Reinforcing the Robust and Sustained Efficacy of EMPAVELI® (pegcetacoplan) in C3G and Primary IC-MPGN to be Presented at ASN Kidney Week
<p><strong>EMPAVELI在治疗C3G和IC-MPGN方面显示出持续和显著的疗效。通过一年的随访，EMPAVELI维持了68%的蛋白尿减少，并实现三分之一患者的完全蛋白尿缓解。间接比较显示其优于iptacopan。此外，EMPAVELI稳定了肾功能，安全性良好，无新安全信号。</strong></p>
10-20 11:00
美股大行评级 | 贝莱德、花旗、摩根大通、富国银行均获上调目标价！汇丰上调超微公司目标价升至310美元
今日重点评级关注：Roth Capital：维持Cingulate"买入"评级，目标价从10美元升至17美元；JMP证券：维持BioCryst Pharma"跑赢大市"评级，目标价从17美元升至27美元
10-16 10:43
Expert Outlook: Apellis Pharmaceuticals Through The Eyes Of 11 Analysts
11 analysts have shared their evaluations of Apellis Pharmaceuticals (NASDAQ:AP...
10-16 06:01
Wells Fargo Upgrades Apellis Pharmaceuticals to Overweight, Raises Price Target to $32
Wells Fargo analyst Derek Archila upgrades Apellis Pharmaceuticals (NASDAQ:APLS) from Equal-Weight to Overweight and raises the price target from $29 to $32.
10-15 20:44
美股大行评级 | 潜在涨幅485.44%！Allarity Therapeutics获机构升目标价至9.25美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持Allarity Therapeutics"买入"评级，目标价从9美元升至9.25美元；JMP证券：维持Crinetics Pharmaceuticals"跑赢大市"评级，目标价从86美元升至143美元
09-29 09:15
12 Analysts Assess Apellis Pharmaceuticals: What You Need To Know
During the last three months, 12 analysts shared their evaluations of Apellis Pharmaceuticals (NASDAQ: APLS), revealing diverse outlooks from bullish to bearish. The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
09-27 02:00
Goldman Sachs Downgrades Apellis Pharmaceuticals to Sell, Lowers Price Target to $18
Goldman Sachs analyst Salveen Richter downgrades Apellis Pharmaceuticals (NASDAQ: APLS) from Neutral to Sell and lowers the price target from $26 to $18.
09-27 00:51
Why Top KingWin Shares Are Trading Higher By 87%; Here Are 20 Stocks Moving Premarket
Shares of Top KingWin Ltd (NASDAQ: WAI) rose sharply in pre-market trading after the company announced it entered into a sales contract with Walker Times International for the sale of 10,000 units of TK-D2C AI Robots.
09-26 18:25
